Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.

Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C.

PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6.


Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.

Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, Gassner C, Stubenrauch KG, Munro K, Augustin HG, Thomas M.

Clin Cancer Res. 2013 Dec 15;19(24):6730-40. doi: 10.1158/1078-0432.CCR-13-0081. Epub 2013 Oct 4.


MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.

Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods R, Jallal B, Ricketts SA, Lavallee T, Coats S, Chang Y.

Int J Oncol. 2012 May;40(5):1321-30. doi: 10.3892/ijo.2012.1366. Epub 2012 Feb 10.


Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors.

Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, Ellis LM.

Cancer Res. 2003 Jun 15;63(12):3370-7.


Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.

Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, Brinkmann U, Weidner KM, Regula J, Klein C.

MAbs. 2016;8(3):562-73. doi: 10.1080/19420862.2016.1147640.


Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.

Sarraf-Yazdi S, Mi J, Moeller BJ, Niu X, White RR, Kontos CD, Sullenger BA, Dewhirst MW, Clary BM.

J Surg Res. 2008 May 1;146(1):16-23. Epub 2007 Oct 22.


A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.

Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC.

Mol Cancer Ther. 2010 Jan;9(1):145-56. doi: 10.1158/1535-7163.MCT-09-0554. Epub 2010 Jan 6.


Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth.

Cao Y, Sonveaux P, Liu S, Zhao Y, Mi J, Clary BM, Li CY, Kontos CD, Dewhirst MW.

Cancer Res. 2007 Apr 15;67(8):3835-44.


Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2.

Reiss Y, Knedla A, Tal AO, Schmidt MH, Jugold M, Kiessling F, Burger AM, Wolburg H, Deutsch U, Plate KH.

J Pathol. 2009 Mar;217(4):571-80. doi: 10.1002/path.2484.


Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.

Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G.

Cancer Res. 2003 Jun 15;63(12):3403-12.


Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling.

Currie MJ, Gunningham SP, Han C, Scott PA, Robinson BA, Harris AL, Fox SB.

Clin Cancer Res. 2001 Apr;7(4):918-27.


Angiopoietin-2 promotes inflammatory lymphangiogenesis and its effect can be blocked by the specific inhibitor L1-10.

Yan ZX, Jiang ZH, Liu NF.

Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H215-23. doi: 10.1152/ajpheart.00895.2011. Epub 2011 Nov 4.


Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis.

Fagiani E, Lorentz P, Kopfstein L, Christofori G.

Cancer Res. 2011 Sep 1;71(17):5717-27. doi: 10.1158/0008-5472.CAN-10-4635. Epub 2011 Jul 21.


Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases.

Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M.

Cancer Res. 2001 Mar 1;61(5):2145-53.


Angiopoietin-2 inhibition using siRNA or the peptide antagonist L1-10 results in antitumor activity in human neuroblastoma.

D'Souza SS, Scherzinger-Laude K, Simon M, Salimath BP, Rössler J.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2017-26. doi: 10.1007/s00432-012-1282-3. Epub 2012 Jul 10.


A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.

Sato S, Drake AW, Tsuji I, Fan J.

PLoS One. 2012;7(12):e51964. doi: 10.1371/journal.pone.0051964. Epub 2012 Dec 14.


[Effects of anti-angiopoietin-2 antibody on vascularization of an implanted model of human colonic carcinoma on chick embryo].

Wang HL, Deng CS, Yuan YF, Qian Q.

Zhonghua Wei Chang Wai Ke Za Zhi. 2007 May;10(3):278-80. Chinese.


Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis.

Holopainen T, Saharinen P, D'Amico G, Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M, Heloterä H, Tammela T, Benjamin LE, Ylä-Herttuala S, Leow CC, Koh GY, Alitalo K.

J Natl Cancer Inst. 2012 Mar 21;104(6):461-75. doi: 10.1093/jnci/djs009. Epub 2012 Feb 17.


A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis.

Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, Bates DO.

Microcirculation. 2011 Oct;18(7):598-607. doi: 10.1111/j.1549-8719.2011.00120.x.


Functional differences between two Tie2 ligands, angiopoietin-1 and -2, in regulation of adult bone marrow hematopoietic stem cells.

Gomei Y, Nakamura Y, Yoshihara H, Hosokawa K, Iwasaki H, Suda T, Arai F.

Exp Hematol. 2010 Feb;38(2):82-9. doi: 10.1016/j.exphem.2009.11.007. Epub 2009 Nov 26.


Supplemental Content

Support Center